Trip‑Free Psychedelics via AI

A startup mapped 70,000 trip reports to drug data and produced MSD‑001, an oral 5‑MeO‑MiPT that in Phase I was psychoactive without hallucinations. Participants showed heightened emotion and psilocybin‑like brain‑wave patterns but no 'oceanic boundlessness' or self‑disintegration. If therapeutic effects track neuroplasticity rather than the trip, treatment could be shorter, cheaper, and safer to scale. — This challenges the dominant 'mystical‑experience' model of psychedelic therapy and could shift regulation, insurer coverage, and clinic design toward trip‑free agents.